Welcome to the future of medicine. On Wednesday, Moderna and Merck announced that their experimental mRNA-based cancer ...

Investors are trying to digest the Treasury Department's buyback efforts on the long end that broke yesterday.

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

CPA and market analyst Dan Geltrude discusses the personal impact of the Moderna and Merck melanoma vaccine breakthrough on ...

Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of ...

The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and ...

RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ ...

Merck Foundation ( the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and Asia and their partners including Ministries of Health, Medical Societies and Academia, is ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.